<SEC-DOCUMENT>0001628280-25-035190.txt : 20250717
<SEC-HEADER>0001628280-25-035190.hdr.sgml : 20250717
<ACCEPTANCE-DATETIME>20250717152911
ACCESSION NUMBER:		0001628280-25-035190
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250717
FILED AS OF DATE:		20250717
DATE AS OF CHANGE:		20250717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		251130418

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk07x17x2025.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i53aa640b4f384670a81d7f2cde5117f6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the month of July, 2025.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">July 17, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a07-17x2025embracemhraprfi.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated July 17, 2025</a></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a07-17x2025embracemhraprfi.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i982cfd4720214c309fd2cdbc8d849477_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">the United States, Europe and Australia and will commence imminently -</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- PARADIGM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%"> comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH&#174; and EMBRACE&#174;) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 participants - </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- Dosing is currently underway in the first pivotal study, APPROACH, and patient rollover has begun into EXTEND -</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8211; July 17, 2025 &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> (NYSE American&#58;CYBN) (Cboe CA&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has received approval from the UK Medical and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) to commence EMBRACE, the second pivotal study in PARADIGM, the Company&#8217;s Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The Company previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for CYB003 for the adjunctive treatment of Major Depressive Disorder (&#8220;MDD&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;MHRA approval to initiate the EMBRACE component of our PARADIGM program in the UK marks an important step forward as we advance our lead program, CYB003, through the regulatory process,&#8221; said Doug Drysdale, Chief Executive Officer of Cybin. &#8220;The Agency&#8217;s decision serves as strong validation of both the quality of our data and the urgent need to develop new and effective therapeutics to treat depression. With expected enrollment of 330 participants suffering from moderate to severe MDD, the EMBRACE study aims to generate critical late-stage data that, ultimately, may lead to transforming the standard of care for patients in need.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;There are encouraging signs of clinical and commercial success across this sector, along with increasing political and regulatory support. Health expert Dr. Martin Makary, Commissioner of the U.S Food and Drug Administration, has publicly recognized the potential value of these innovative therapeutics and has stated his intention to prioritize and expedite the review process. The commercial success of esketamine is also a positive signal for the entire sector. In the second quarter of 2025, esketamine sales totaled $366 million in the U.S. and $414 million worldwide, representing 61.1% growth year over year in the U.S., and an annual run rate of roughly $1.7 billion.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> These positive factors contribute to the credibility and opportunity of the work we are doing at Cybin,&#8221; concluded Drysdale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">EMBRACE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8482; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Study Design&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">EMBRACE will enroll 330 patients suffering from moderate to severe MDD (MADRS&#8805;24) who are on a stable dose of antidepressant medication but are responding inadequately. Study participants will be randomized 1&#58;1&#58;1 to receive either CYB003 16 mg, CYB003 8 mg, or inactive placebo. Each study arm will evaluate two doses, administered three weeks apart. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">EMBRACE is the second Phase 3 randomized, double-blind clinical trial in the PARADIGM program, and is expected to enroll participants at approximately 60 clinical sites across the U.S., Europe, and Australia. The first Phase 3 trial, APPROACH, is taking place at approximately 45 clinical sites across the U.S. Participants from APPROACH and EMBRACE will have the opportunity to roll over into EXTEND after completing the 12-week, double-blind, placebo-controlled treatment periods. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Sources</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt">Johnson &#38; Johnson. (2025, July 16). Johnson &#38; Johnson reports Q2 2025 results&#59; raises 2025 outlook &#91;Press release&#93;.  </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">https&#58;&#47;&#47;s203.q4cdn.com&#47;636242992&#47;files&#47;doc_financials&#47;2025&#47;q2&#47;2Q25-Earnings-Press-Release-Final-7-15-with-Attachments.pdf</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, &#8220;forward-looking statements&#8221;) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221; or &#8220;continue&#8221;, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company&#8217;s plans to enroll participants and add additional clinical sites for the PARADIGM program&#59; the timing of commencement of EMBRACE&#59; the Company&#8217;s plan to enroll 330 participants at 60 clinical sites across</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">the United States, Europe and Australia for the EMBRACE study&#59; and the Company&#8217;s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. APPROACH and EMBRACE are registered trademarks of Cybin IRL Limited, a subsidiary of Cybin.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; implications of disease outbreaks on the Company's operations&#59; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company&#8217;s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sedarplus.ca</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> and with the U.S. Securities and Exchange Commission on EDGAR at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sec.gov&#47;edgar</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor &#38; Media Contact&#58;&#160;</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gabriel Fahel</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Legal Officer</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin Inc.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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MX+XF2J$\^4 <A:@"!<P\=C&QF_R\B3JQH<$#::\P%2*+%\;1B[^9]@]3(>I
M 3.->YFH=\3)A/O*(4,ZM$>?0C%>MC3QG?"$'( +PE2(.E# ;,?53?]N(EAZ
M/R#ZA$[XCPM3(5K#Y\>;0^(H1#4H8#;GX:;OFAXU>;5\O-7$/900;;B%R?MS
M0RZ &D6+ZE# 7,Q]3,>;CC754!Y2$IR'KA&F0C3BC7'TY'EQ%*(J%##G\SK3
MYTP/G;Q:?BB#X=\K1!/P/_:^FOB2Z0MA*D1=*&#.YLZFKYJ>/GDU+O"CU?V1
M:,++X^C)07$4HCH4,"_+"TQGFFX_>35..!+#]U:(M<"D W]D3VA3=T*8"E$?
M"IB7P'M!7:)6N $<BX18"[KB>*/K %$U"IB!1YLP)Y?SS25L9BJ1T"&&#XW,
M'QBFKG@VG!;"'07,T$'D&-.-)J_$2NBGN>R9P:(]SS!=)4S=H)O/?X:I$'4R
M]H#)EW3O,!5K\)0X"C%EWSAZ0M-I(:IFK %S(],9IKM/7@V'V=V^R\+#\<IA
M*L3D^N(?PM2-GYH^':9"U,L8 R8FZ=\R>6?X>7*>B:0;[G0>:Z(;"G>*'(\B
M,E@?:>(X^9.F/YA*<473*\-4B"([09JL"U$]&ZQ?/WO3LNXX/+F7CE>82APG
M>4&0?*?I8R:Z-31E8Q/=(DH>+V]B4N?[<<,B[=UAZ@:E)#<(4R'J9DP[3(KQ
M:PV6!$IZ"9*E2QU:FV )--K%9*&DT<*SXRC&BW<++]#IA1@,8PF8=%.HT9^2
M;O(/,Q$HO\,O9'*$J41]'#S)=/DP%2-D&],MP]2-"TUO"E,AZF<, 9,CSAK[
M/;[,Q /HPY-7?K X*&$ZL*%IQS 5(^3Y<?3D_:8_AJD0];/, ?,ZII--NTU>
MU</73=B*8<%7BEU,) YYHRX2X^2?3 \.4U?H+2O$8%CF@$F39[HIU 1=Y/&H
MI:2E)'\UE3B:Q9C]5F$J1L2#XNC)#TV?"5,AAL&R!DR")4DT-<'NC!*1KOB(
MB<#IS:YQ%./AB7'TY- X"C$8EC%@TDO/NT=?+H\PE6B%-(\_F<X*4U?&W,5E
MC-S.=(<P=>,BT]O#5(CAL$P!\_^:Z'9PC\FK>J#4X]@P[9S/QM&3+>(HQD&)
MNW8,.2X.4R&&PS(%S&^;[A.FU;"=B5*/ON!HVIN;FQ0TQP'N4CN'J1M_-AT8
MID(,BV4)F*2GWSA,JX#C4.K6R-+M$UJ6E>!N<13+30DCC*--?#^$&!S+$##Q
M\/NW,*T"ZLJXYSM]\JI?L+(K<?2E>\QQ\/@X>H(]Y5C!^.,VINU-),\]SD2Y
M#CMY,0"&'C"QZMHK3*OA?B8<?&K@MZ9?A:DKWHXOHCXPJ;AFF+K!G?JY83HJ
M:+9-'L./3=\T44[S7M-;35AAGA/GHG*&'##IFO#2,*V"'YGN8OJ/R:LZX+[H
M?\/4%>XQ-PA3L:24N&<<F_$%31%.,M%,X>&FZYO6@MVFZE(K9Z@!D]7OB\*T
M"E@ATG+KS,FKNBAQ7X3SRW7#5"PAVYJV#%,W_MOTY3 =#1\T[1"FC>"HEMP'
M42E##)BLTKQ;#.6 !1W!DN//&FG;^:0)?&[^,4S%$L*U@C?OB^-8P!V)A4=;
MY*15,4,,F*>9KA*F57!?TV_"=%1L%$>Q?+#3\69L;;R>%L>V7"^.HD*&%C"Y
M#[A1F/8.MG-<YI=PT_'D"G'TYAIQ%,L%]]-W#U,W/FXBX64L\%R]4YBV1@&S
M8H84,+DX;W,?4)*_F"BMX$%0.U>*HS=7C:-8+DKD!NP3Q[%P4U/J"4RI!:YP
M8"@!DP)J=G.UP K\6V%:/:6^@&HFO7RP""*;TQ.RQG\0IJ,AYQ3LUW$4%3*$
M@,E*[; PK8('F+X4IM6#OVZIG6")9"+1+P1+[P76(7$<$_/*1Q;QLSB*"AE"
MP,10_8IAVCMO,'TB3 ?!AJ9KA:D['$N+Y6+/.'I!*<F)83HJ:%Z?2@FC$>%$
M[0'S Z;;AFGOO-GTU# =##<TE5ILE#!$$/U!&R^,-SS9+XYCX^IQ3($J %$I
M-0?,%YMV"M/>H1FS]^J["TH:TFLEO%QX)^9<8,)H?8RD/E=)(J2N6U1*K0%S
M:U,M+8!H&_:O83HXR-8K!<=M8CD@@<N[@<&I<1PC-,A.H43O4>%(K0$38^(:
MP%;N7F$Z2*BI*P%&#71"$<L!)SDYQXBSH.7>6$DQ,L&<_6MA*FJEQH#Y)%,M
MO2V?;!KRT6.I@$G'"?4T7![P9O:$THA:%KU]\)TX-H5CV-W"5-1,;0$3[\4W
MA6GO[&]Z1Y@.$KJ);!JF[M"B2"P/WJ<HY!^,F2^8?AFF"R&XDMBHK/,!4%O
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M)$MA:Y_!$OHV>1>7Y0%QS(&5'AFJ74'Q>%_!$JC)]"KR]SJ.X^B5.[YE#Y9
MEG\N.?>0[*R\\ QP[/!R80?Y"A,[-TXC,;9H4W[$B0EN2%R5<.K$=4]N[.(>
M'M]<'(UX[\F:)I< HP<6&W<TL>CDS_S[SR;W#V6UT">4DN2N"H4O?#D\CE$Y
M)EN=;%(*W%GV"]->V32.N6P;QQPX>GJDB:2?KOBUZ3,F3B@PBL #EK(&C!"H
M6?V=J128&C3Q!9Y'$^_8M?"Z1P7J)[W(,6,G\>\=)K+<]S7=R)0+UV]\)NCX
MDIIG@,WC]!Z>X$T<Y,J!YP"UJ[Q_=S%]U\11/653DUB9&S"]CA!2X4LEZL++
MYNO]<2P-*]<V'JDEN5,<<V"7BCE\+MSKL,HNS3K34::'F%@P4&)#$B$/14PO
M^([C1\O=('?C')]Q3$9++V\P'<\AIXS',V!ZU=\"[FEMH:\I5V6T#2ME9D/P
M)9/]WTU-3.6GD"=P6)A.2J_>8N(XGN\>"TU.3%GXX,',]PCG.&ID)PY1.7>8
MU UQ,=J760'_ 'KIB7K@0\RQ2R[<6> <51J^'-P[U0)'T(\+TV3X[X=@FDWO
M2AZJ]*],@:Q2=H4\_#S]JVDYEM(2C(<LB3&I;0WQ%^9T)A=JXC'VS]T, <&!
MYSP[_Z:03]+U1N:O)HYX%QT?<X(P;7K SI)@.>OO^T<3V>#L1#F.Y=_/^[IW
MSIO*5K5/9Q\N9$5=>!G?=['CXYZ'K,::\#B2]=BEEH0[*)*2N&=-#9; 0Y*=
M*4E)%_ +3J1F2!,P<W:87G68]S%Y!$M@=]4T6/+OY\ZOCU,_%D_LA!?E $QW
MNW1.(EC"]+\AF8A3#DXV6(!Q'8"Y!4EXT^?1'CEO+$=9?<%*COZ"HA[XT.X1
MIEE0R^;5\'@M^+NRP\FY<RJ!QZZ:8\M:X8B5XSH2*;Q@5X&'ZR\FK_))_0RS
M,UVK*7H3O(YD/5VCFMY?LVCAGK)/>T1*0CA&G?>=OG\<.<J=0NLW(+$-$?!I
M[@W3Q*0/QO'&J0$3YP?.?_LBY5Q=E.7?3!Q;Y$)#74HL2D**NE>"C2?<I>06
ML.?XF9:"11#9B*S:2]1+LV.X:YAFLY4I)5LYU]J.@)G[LP=/$W<2L!9!D"0I
MINMZZ5EP:C2O&\TTZ8CN.ZO!&0N/8=R?L )DL4#"$G 7"]=*#9@>.XD<5JX0
M1!UX]:WT<@A:"[+C2C08IUDR1SAD Z;"+H5:S%3X[ZDMJXEWF[B;*WVO>H[)
MZ^>:<GJ6>SK D6SNB0=!R^,>%%CD++K?9S=6JO%U*B2'K96 ,UV0<)R_FIU-
MN%KA+TP'(;S)R:6 O]=&IP;,4IE/3> ?<7R8BDJXF\GC0<V7C]U"*?C<4G_E
M#<=@U)EQ#T(2"O,4^**F-/N=0BI\WPW<5[*WB?>[*Y]G[J0]ZBE3LDRI%<R!
M'6;N/28[)"^X:YY7LD?-8JV&,30$F.4/,'4K6MD8>YJ'P^>&DP5&?A8X;TU_
M'E/'I#^D!$SLC+Q6,2EP9"?JXMEQS*5DYWGNN:9'+)Z0_+;ZZ"K'3"-GE\%Q
M8BU@ M'8+LR10^.8 ^]CVX5'KD$Y#^G<>\Q46[Y9S$N((\< AYR:F557/?TW
MK;2@G 9,%@?82?+?L0-E 30]L9C>?9Z;$C ?&,>^D-%Z7?"!\VA43#U>J39>
M9"^>$J:N</R*P<)JL!-+[;"2X_A"?\T:X$BS=.+66F!ND)O]3+!LZY:36DXR
MA9][[@Z3DQXO3HSC:C"5H"ZV=C@E6%V?.74.XXX2>SZ8WOFS$9S"G2Q,=ZG<
M:\()*0%SQSCV 0VBU<:K+B@/R'G(3RE92H*Q=:Z+RVKPG9T60,\BU8$JIU2K
M"Z.!19#\U?>]UD%QS*%M\E1NLA7?H9P=)L'!*Y$-6\I9)3\<P7IX1'?%ZI,>
MCF2GWUGR8,@7(/?@Q::51BFX_5 BQ[$LM<)DGE.;>W#;@$DFV'W#M!=4>UD?
MT]57#A1(?SQ,W2%KCKL]3T@<6O3@^',<NV+:^:$O2!*A1=DT!;]/^)F3!)0#
M+=?:X.'?FG,</STV]("69]-RBRED.?=18YD#GM:4O*R$4R'<@<CH9_-%LA8.
M3Z>:IF"\3K E:!),64#PV?Y]VX#I6>/3%LZ5:_@RBDO@&,K#:+V4;^S#3-X+
M/%::/#P6D7)Z ZD]%3WL\'+@/?ERF%8!9MHYM,W3R"TK@9P=IF>9W^KWCI*+
M::'_T, ?=C684W"TS,^,3& \8]EYLK.D](G=)XMXW(!P+B/H3KJ_M/U2][F[
M).6W*S-NT0RO;&D*VKTA">-2K7F<(!&@R>XQ]>&7VMZK3?<';R@=Z;*S3!-R
M:[57WFDM@N<HA?.YY 1,3X>G3\81.(Z<5]N8"P&+'K1'FS"C\3*@F()!^ZR=
M.W[%NYNP).1.$QL\G*,XQ9R:NK/+Q(B=@#JA;<#L\\BGQ,-/Y/'$..; T5D)
M/U?N+;WLQJ:0S,(]^B*XATPM[T@]RNTK<YUN%B5*=7+)Z;(!;>HJJ7_U")BI
MGU=.>G!0\H#OXJ_"= +)<JFG)6O!KHTL6Q8E&$ZP\.990ED,OT992!O_VGD0
M+.GG.@LJ+OC>L(,D>')'RPZ3Q%;N-SF2O53-9MLW8F7]2I=PGLX%K*@'^B1Z
MM!'R* -8#76ZWCLN:@J;)K/0VQ+7GK80+%.;X_:1(4L21=\=B]8"=Y:IT78*
M;;)>2?C)+0F!U$46WT4O5MH6DOCC[>!#D@UQY'#3C_F%57!?R$Z/_X_7J<7C
MX[@6-$HG>)+@PVD7^10S/SMM B9?R"XZ2,R"N\N+PE14@D?M)5\.;P<83 ,\
MVQL!]QMM:@I) $DQXL82,*7G(PD,?>PPR6G("4HE8?&18X+!KK%I$,PM*9F"
M<44*GN4DTVQ13E,\<U:X:N Z@^]GDWMZ=IATWO$X#F;GRB(VFS8!LT_OV)J2
M"41PHYG6,>5  _#4.[M9L-O)L::;!?64;7_/U.#%20JMA=K":MS[^'D16(AY
M=.,O2>IN'0A>37=\.7:&*TG-DDWQOIT%[CXL,E@ D$GJ!0DT9*JGU,>2N)?S
M<P2N2$A<RJ9-P/0R-TY!M9=U0:V=Q[T&G?0]*>'D0[NDMJ1FK*;>V_1A?.UA
M05>:V<U^FX'O:-/ZXKX#9LKQ_RQ(O@&:$WB" ]'4#* MG+IX>(>[;/C://0H
M4.\##^<.X4MNDV,XUW1JF+J D<"T&X$7V-[-ZFRPB-0O9VJ&8->Y!<\QE>XH
MXT%.NRV";=. ZW4DFQHP;Q+''+@>(5.5THHM^04G.-K-S5CVL$-MD_6\)DT#
MYN:FOC)DN;_DARGJ@(>SQ^)IGDM.6^B4@G>I)WS19]G>+8)CO-0D#([$4NCR
M_O(;IE>&:=6P.\PYJN0.M.ESQRM@IB3]\%SV6"BR &+12<*-%_BR>K@^L6&B
MF74.+GUBFP;,/KNXEW* $6E@8NY!2C":Q;8FG#H\(9BG?M'97:;N%-AUI\""
MMBO8@0P!'I Y1Y7<FS6]3_:R74Q)^O%JYT99S$/"U 4R7#V/[7/+"G%NRK;P
M;!HP5]L+=05'(DV:F(KN\'#V.<_TRS#-@N0CBIT]X0@V)W$H)\7_[#BV@53X
MKO(+2+[[8IA63^ZNF^S?ID>R9-1ZD++0ZM.P8BU.-WE<VZPD]WO.XBG[Z+II
MP.SKA\(7M-:T]3%")B8=UG/QNKMD%YA2OC$/[BUSR/'T;',DRR+V-!->EQXU
M@$WP\ WNBEG]$-O0IMM,GSO,V@(F[YM+1NHJN JX($R3R;[K;QHP^^J"\.$X
MBCK@."[UN'$E'GT2<>;P;C7'[Y>2Y#.%8\#4!S6[F2:[;KZ+6-&1==AE(A[%
MW4,Z[=DUCJE,O$,;XI4EF[+X\[HB\8+RD932J"9\/HZIM#74OPQ- B87RM..
MTUV#?ZRH!]QN<L$=)O=8C[(-;^]2S,-S[\LIMTD%4_>?A^F:<%3,J<LC)Z^Z
MY25Q' ($D5RK.'8T37$IBC?:)OT0J#W<MKS@&#8U<:T)7XIC*IT<R?;U \'/
MD%6MJ /NA#S2UW.3?2A"GM6K+X<WFSP<AW(<AJ@U7LO$@5I04O-Q2>D#ZD-I
M^304/'HVMFEF[G4MT/9(EB-&ZD5K@.]0:0/^E#O^E62W8&L2,/LJ)\FMW1&^
M[!3'7'*SW?")S6W6NQ)V$GN&:18D?F#]E<HL _KKF2@FQTC>T_ZL+1S_IK8=
MZX/=XIC#^7%<!%<47@&S[0ZSEMTEGP^/[] B<G>OV<^-)@&3UB=]H(!9%QXI
MYQS'TIPU%5KP>*:^@T<2$^P8QU16FW-0!TKK(7KW]4V);C*EX/.1FP3U%],L
M8_!9> ;,MK]/UX85L\!8IJNVCSP_+M4]I"79/4N;!,P^3)W!NUQ I+.IB8[C
MN>0TH<5]Q-/L /"I;'/T-H^<8T *Y/'5!=H+T6D#+T^O[,M<O WR2T&=G<>Q
MX(FFIOZE'*.F9+?.HJTS45_/YBDD]Y"$]IO)J_*0@9MCJ,\.,^L[U21@=ED4
M/84[DR9]!T4W>+4/(KLS%1YBGKS(Y)6%S='85F&:!*WK6/VN,]' M@]OV+6@
MKV3)1 Y/\!+V\%5M8\5&L,PNB(^T/9+UR"G(X7FFW'O%MN0TF.;]S>I;NBA@
M$HV]G/#;<&8<11WDUK0!Y1HTCDV!A!,7:ZL('>4/"E,7,)?. >,!S!SZ;'"P
M%D/)5"?ABF/L7.@8<T*8-L*CS&I*FYTJQ\XN_JB)8%5'3\NNR:W+SRH!6A0P
M"98I_H:YJ)U77:1VWU@)GL IX$?I>6])]O5:'=A3R3VNIG3+\\'K"1WW:X?%
ME-=I 7ZJ;1*</$TCVCQKZ4V<M5O*),>@(X?<X]^B =-S5=^&W'H;X0</\ER_
M2AY *:VW]C ='*9NT$PV)W%@-21J>"4.U09W5%ZN3*7@"):Z7LJ-<B&!I:W_
MJ6<?TC;UG-Z=>=I +]PV3DB>Y ;,+*/\6@-FJ@FU\(?[M%PG$[PEV]Z#T0SZ
M;6'J!@]#[].+QYKPM%U&"$2UM_$ZV>1EK,*]-D&S#9X!<T-3T_O0/G)+@/>(
M*XV^P. CAZS2DGD!D__-JVU-6U(;Z0I_LHM]C91,U&/CZ 7WXASO>O.D."XC
M-5^-L+/G),KCN@ N-'$<VQ:/G>T4CF2;[C+[R"VA9MGS[C^%W 5<L:0?=A4;
MAVFGL-5O6C0LRI-=NV20:=D&,F*YH_&"WH8E[ES(CJW-R].36IVVJ#_D,^79
M=A 3^Y2C>D^G'18!36LQ,;7HFB[,"1:1ZU-;[$B6@.GQL&S+MTQK682)[O&H
M!?QN')M K:9'"[&5D.13HNO-,^*XK+3Q4^T*/AL$2\_2&P(EY3PI++K6:@/!
MMVDM9M<!D[IXKE;ZYJ(XII*U"9SWPR98]G$DF]M96_CB<4=#JOXBN+OYM D3
M=$^P2>/W]8:%Q)/#M%>:%MBWA<XI;18ZI2&?XA@3IP_>&<4Y1_5->V8VI>F1
MK.<)S")H"N#=&2B5W!UFUE'VO(")-V8?3B,Y[96$/QX/A":K8:SAO"VVL%?D
M(5L".C-X[B[:0F(<#S%Z8I: 8.D=#%+ RQK3>0KD'\TO.'..J2]3^UDT+5/Q
M,&AH"C[2GIGE.7"]DD/6J>F\+SP96ZAKL 43]4 R1"[SZA19*=/G;IO)*S^P
MF\OU=YV'1ZNS5(XV<7]*.S(O6[;5I)I,>("##28$- BG+R5MS3RS45>2TY*M
M+T@TZBHSFW*PW'9\GN#SFP-'LFT]>__.O(#)67I;;T,/%##KPL,G<JW Q?'K
M629*2+RAWK)4K1A=2?JH@V.53V/D)YJF*^U2S7IS[? (Z/S<V8ESUXMQ_K--
MSS3AE\N(GFMZF>D($PL  B2[2;QT2]>WOMJ4TPP /+-DH4G^!L]EKQZ<\R C
MU?N*))?<@,DF,/FJ<8/UZV>?NJP[[DC,I%]@ZO)R&6-=[BIJ. H2@3N8:-^3
M"Q9K'S7Q@*=NCF.>4AFF/*1+]N9CU4W]99?@N$. 69VY2ONO$AU-:%+=MA4;
M+<@(DF0D8Y9?,]QK[Q"F6?!O]NRL1 ;P(G]6:@GIW.'I,C0+?H[>O6=S(8&/
MYT@.G&8E)3#-VV%2$U3JN&<M6%TJ6-8%-90>Q>NX@QQE(I"]U%0J6!)42C>R
M?7 <NP*W(YI(SRKSR#&CG@=W>VW8Q43@8!=9>[#$'M$C6 )'_U[P/?M9F,Z%
M9W/I8$D-;FW!$CS>[^3:\GD!DTPT+Q?^IK!J$G7!!W0HG6/PJWUMF!;CX:8N
M$RXX@GUAF,ZDR0,VA3:!F'NA]X7I(/#<D7O<\4_AA*W)[U<Z6(*'D7T)/ )F
M<H;QO(#)#Z7K@$G'!E$?I\:Q9K#,VCU,BT)+HZX@:WA1("KQG:$,J,W][YOC
M. 3V-WEV8.&.W^M4[/MQ7(2G6<(LR!IN^G?IFFH#)O_;O/^]! J8=>+5":(D
MVYI*^YYBP]:%LP_%V03+STY>S:=$K\H+3$UJ9X'[:%IK#8$WF%X2IF[P7G'$
MZT%39Z62UU:<+)"(52L> 3,Y+Z?K@+B('\=1U 4^K+4>R^([3!##(:HTKXMC
M2=C-W\K4)%B"UQWS2MKL+A\?Q]KA9."I8>H*6:U>F?W'QW$1N;6(\]@^CK7B
M8=21W%2DMH")HX2HDWGW:'U!H*#I<A?!_!:F>X=I,<C<I,2FS:Z1.Z\4<_MY
MM F8-3:]7@UE+2\/TR)X+-;(WVB:C<[/O(1]*,?5M1O'T$TFM[0DN6/)O(#)
MMK_KC%6.-T2=?,Q$%G--<&S9U=^I]-TE#\S4S$UO.\DV+91P!*L9:CP/#]-B
M>)1=M>G.P\\GM\W5:LB*]CZN+@%WQFU;L*T&G_2D^MEY 9,53)<FZ-3G>13)
MBW*4L"9+A?*%,\*T.#B#E*AUG,*]T=9AFH3W^]#FB+<6R[19T'J-6O+24".;
MRQOCV 3NN+V?E71K&0(<1^<N%ECD)1D_S N87*[F;GW;P.XR=^4@RL)=)HXL
M?<(B#E.-U.X2*9 $4>KZ@ATRP3+G.L*[7JY-1XBN%BUMX.]$$AB=;[J (_$<
M*T$*\=O^]Y[)7MR;E_)<+D%NK@L+X"07NWD/ <[)/3*2FD+[)9D6U,_33;EV
M8JG@@$*F:DJCWQQ*]0'$%I B_]P' /5[GFXS;;[W72Y<FD =+O>JGN]'$W)*
M:W"F:@N+5P]X[FX7IH,AMT\K<2^I-&=1P,SM/=:&TB4!PH^[F[K.FF770'#I
MNN74+4W)20)SX/..K9K7HO2X.'K0YBH&XX3GA&FOD'C#'3!.3WV ]VT*W!NF
MY&YXG2I@?]?EU9L'+#1SX#O7M&SJ4LP+F*3O-G&=\*)47S_A#Q\XNMUCEMT%
M)&ZP:^AR 3>E5$T:=Z*4Q'C1UO=U'FT?H*\T>0;L-O!9Q,R=Q52)OJ=-89??
MUJF,$[4#PK0UM,/+39+\5Y/73K5+>*]S(&<@Z?IO7L D B=%X404,(<%#U7Z
M,99,%L P@2/8+A(W9L$]1XED'[ID-*VY:PJE(#17]B!EQX%EX&O"M!-8/+W)
M1+E/EW_N/ Z,8U,P$L^YADJM*_V;Z0&FCTQ>#8_<>_/D1<*\@,GJM\NLU5)M
MBD19,%(G:85D((\=(*L_=BQW,3W,]$U37QQBFO<=28'[5UI=E<#K.#+UF)B=
MWLU-I>ZY6533G86=T>:F)YO:FL27Y*VF)CM&$KWN8<H]H7F_B?>@*627<@1,
M4VY/>\"N^:4I)Z&+9@9)S&OOQ0>?0M;2/>FF\$7HNF62\ 6/1DI/: W5QD*.
MA=E)I@^8V"7U<?2Z&G:7WO?JIYEX4)9DG2G73& ?DX>K$7U#Z;+"W^<VIK9=
M(BA9(<&#'<'G3">;O&SH2L)W *.$ZT]>71I.%ZCI]:Q H/?KBTS<B<_B&Z9W
MFFA+YWD-T"?7-)&PU!;>AV3/Z7D!$[\]CL)(X>^"MYF&8K,E%L.=$KTTIP]*
M/D]TS>>XCX<>R2*DX^,LPD.QR^/_)O#9/RA,76!1L*FI='(;Q^283.1 _:)W
M20:-'.CU2.-M&OA>QT0]'"T$*2+G<T'.!+L'=D+L',D>SKVOZ@NZ/7%,3>]%
M_FU\SKEC+=D@GP0U%JITC^'//-_$GYN;)%,K>YF.#--&\%[P/$IF7L#DX?9\
M4^JE=%N.-M%)7H@:(,!YNMC0+ND]85H<=NG<4:7"D>=0[[?$N,#PH4G9%\&2
MJZ.L1-9Y]S,X*K!"Z8HDJR+A O=!6YEN-WDE6+EZ!DN.$KL*ED /S3;]+%?3
MY[VQ$&W@#I><@+6,'[A+IU;XSJ;LJH]Y.TP&NN1W53J@.\SNV<E$V00?IBDX
MB/!PYV0A)5MRZ. "0KH^7>T]X,Z(X\><;,@42.Q(\=D]U\0"2HBAP7TYG7XV
M-'&4S]VWZW'TH@S +G>87701%Y=PE(DDFY7!$KACXOX.8X(D^ZB!0P*%5["$
MG4U=!TO %6F7,&T%NV$AA@B?7;+0#S5A]>=^=[LH8)*8T=4N@\M_41ZRR\@X
M?,KDU=JP4B-+>FQPU^@%Q?R\UWU!V4';3AUOCZ,08A6+ B89:UWUJ.0H3)2%
MS%7NISBZ:$).XL@0H;$LM9\>4!J3G+[N"+T@,8!HPI=,.,@((6;0I"B;HYTN
M8.<CRD$B"'W[VG0;3S(H'C">NRMVJK68<; (P+%HWA4+1_"I_3B%& 4U!<QK
MQ%'X\T(37J/4PK6AMH;1):%F=/LPS8:DH0^%:35@#KZ%"5_>E>XX6.IQ;$N6
M=$HAN!"CH:: 21K_V'8T74!]*_9U*8PI <33CQ1KN!K!-(&$+A*[-ELACFWQ
M%Q5"S*%)P.QJET'JO7:9OGS2E..>Y-D!HV:XV\7&S0.^+T-XWW#10?)P%J(A
M30)F5_T'<18JT7=PC+!;YTB07G>ID&'95<)7WW@VI,963@BQA#0)F-\SD2W;
M!7AMBCSN9^(8?<?)JW126P<-C8>8O S1\7 ])4R%$,M&DX!)T37=S+N@30:G
MN"SL;NC$OM'D53K<>>8VIQT*B^I1VT![*R'$DM(D8$)7WI(D(X@T\%2DH6XN
MG":4; I=$W10\2JE^(QI3%G%0HR.V@+F3>(HVD%3V#>$:3:>3C>U@REST^_
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M3/N&J1!"](,"INB2Y\:Q#7N;#@Q3(83H#P5,T27GF=JTX**SR9%A*H00_:*
M*;KF':9'F-9/7LWF#R9Z9KYW\DH((2I  5/TP;&FFY@.,9UF(B'H;!/>L$>8
A;FKZE$D((2KA<I?[_[P*ZV0DJ0MG     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
